Evidence Level:Sensitive: B - Late Trials
Title:
Effects of baseline lactate dehydrogenase (LDH), interferon gamma (IFN-g) expression, and tumor mutational burden (TMB) on treatment response to first-line atezolizumab (A) + vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation–positive advanced melanoma.
Excerpt:The RPA analysis included 208/256 (81.3%) patients (pts) from the A+V+C arm of IMspire150...TMB ≥10 mut/Mb was associated with more favorable outcomes in pts with e-LDH (Table).
DOI:10.1200/JCO.2021.39.15_suppl.9523